{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:05:13Z","timestamp":1757703913002},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thyroid Res"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Sclerostin, a product of a <jats:italic>SOST<\/jats:italic> gene, is a protein expressed by osteocytes that inhibits osteoblastic bone formation. Several hormones, including PTH and glucocorticosteroids, have been suggested to be possible regulators of sclerostin production. The influence of thyroid hormones on sclerostin synthesis has not been investigated, so far. The aim of the study was to evaluate sclerostin concentrations in patients before and after treatment of thyrotoxicosis.<\/jats:p>\n          <jats:p>\n            <jats:bold>Patients and methods<\/jats:bold>\n          <\/jats:p>\n          <jats:p>The study involved 15 patients (4 men), mean age 51.8\u00b115.3 years, mean BMI value - 24.7\u00b13.5, with thyrotoxicosis due to Graves\u2019 disease or toxic multinodular goitre. Serum sclerostin was measured by immunoassay at diagnosis of thyrotoxicosis and after 6\u201310 weeks of treatment with thiamazole. The data were analysed by means of simple descriptive statistics of location and dispersion and Mann\u2013Whitney <jats:italic>U<\/jats:italic> test for pairs of results, before and after thiamazole therapy. Association between variables was evaluated with use of Spearman`s correlation coefficient.<\/jats:p>\n          <jats:p>\n            <jats:bold>Results<\/jats:bold>\n          <\/jats:p>\n          <jats:p>There was a significant decrease in free T3 (FT<jats:sub>3<\/jats:sub>) and free T4 (FT<jats:sub>4<\/jats:sub>) concentrations (from 8.74\u00b14.79 pg\/ml to 3.54\u00b12.40 pg\/ml, and from 4.48\u00b12.21 ng\/ml to 1.02\u00b11.07 ng\/ml, respectively, p&lt;0.001). This was accompanied by a marked decrease of serum sclerostin levels from 55.46\u00b120.90 pmol\/l to 35.73\u00b115.70 pmol\/l, p&lt;0.0015). Interestingly, enough, sclerostin levels did not correlate with serum FT<jats:sub>3<\/jats:sub> or FT<jats:sub>4<\/jats:sub> concentrations.<\/jats:p>\n          <jats:p>\n            <jats:bold>Conclusions<\/jats:bold>\n          <\/jats:p>\n          <jats:p>Restoration of a euthyroid state in patients with thyrotoxicosis results in a significant decrease in serum sclerostin concentrations. The above mentioned phenomenon may reflect lowering of bone metabolism, but a possible direct influence of thyroid hormones on <jats:italic>SOST<\/jats:italic> gene needs to be investigated.<\/jats:p>","DOI":"10.1186\/1756-6614-5-14","type":"journal-article","created":{"date-parts":[[2012,11,13]],"date-time":"2012-11-13T12:52:35Z","timestamp":1352811155000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Successful treatment of thyrotoxicosis is accompanied by a decrease in serum sclerostin levels"],"prefix":"10.1186","volume":"5","author":[{"given":"El\u017cbieta","family":"Skowro\u0144ska-J\u00f3\u017awiak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinga","family":"Krawczyk-Rusiecka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof C","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zbigniew","family":"Adamczewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Lewi\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,11,13]]},"reference":[{"key":"72_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00223-010-9372-1","volume":"87","author":"MJC Moester","year":"2010","unstructured":"Moester MJC, Papapoulos SE, L\u00f6wik CWGM, van Bezooijen RL: Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 2010, 87: 99\u2013107. 10.1007\/s00223-010-9372-1","journal-title":"Calcif Tissue Int"},{"key":"72_CR2","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1210\/en.2005-0239","volume":"146","author":"T Bellido","year":"2005","unstructured":"Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O\u2019Brien CA, Manolagas SC, Jilka RL: Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005, 146: 4577\u20134583. 10.1210\/en.2005-0239","journal-title":"Endocrinology"},{"key":"72_CR3","doi-asserted-by":"publisher","first-page":"E1848","DOI":"10.1210\/jc.2011-1534","volume":"96","author":"EW Yu","year":"2011","unstructured":"Yu EW, Kumbhani R, Siwila-Sackman E, Leder BZ: Acute decline in serum sclerostin in response to PTH infusion in healthy men. J Clin Endocrinol Metab 2011, 96: E1848-E1851. 10.1210\/jc.2011-1534","journal-title":"J Clin Endocrinol Metab"},{"key":"72_CR4","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.bone.2004.04.019","volume":"35","author":"MK Sutherland","year":"2004","unstructured":"Sutherland MK, Geoghegan JC, Yu C, Winkler DG, Latham JA: Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts. Bone 2004, 35: 448\u2013454. 10.1016\/j.bone.2004.04.019","journal-title":"Bone"},{"key":"72_CR5","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.2174\/138161210793797924","volume":"16","author":"R La Corte","year":"2010","unstructured":"La Corte R, Trotta F, Adami S: Glucocorticoid receptors and bone. Curr Pharm Des 2010, 16: 3586\u20133592. 10.2174\/138161210793797924","journal-title":"Curr Pharm Des"},{"key":"72_CR6","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1002\/jbmr.479","volume":"26","author":"MS Ardawi","year":"2011","unstructured":"Ardawi MS, Al-Kadi HA, Rouzi AA, Qari MH: Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res 2011, 26: 2812\u20132822. 10.1002\/jbmr.479","journal-title":"J Bone Miner Res"},{"key":"72_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1210\/jc.2011-2152","volume":"97","author":"K Amrein","year":"2012","unstructured":"Amrein K, Amrein S, Drexler C, Dimai HP, Dobnig H, Pfeifer K, Tomaschitz A, Pieber TR, Fahrleitner-Pammer A: Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab 2012, 97: 148\u2013154. 10.1210\/jc.2011-2152","journal-title":"J Clin Endocrinol Metab"},{"key":"72_CR8","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1210\/jcem.85.3.6457","volume":"85","author":"H Pantazi","year":"2000","unstructured":"Pantazi H, Papapetrou PD: Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism. J Clin Endocrinol Metab 2000, 85: 1099\u20131106. 10.1210\/jc.85.3.1099","journal-title":"J Clin Endocrinol Metab"},{"key":"72_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1089\/105072502760043503","volume":"12","author":"P Vestergaard","year":"2002","unstructured":"Vestergaard P, Mosekilde L: Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16,249 patients. Thyroid 2002, 12: 411\u2013419. 10.1089\/105072502760043503","journal-title":"Thyroid"},{"key":"72_CR10","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1210\/jc.85.11.4157","volume":"85","author":"Y Kumeda","year":"2000","unstructured":"Kumeda Y, Inaba M, Tahara H, Kurioka Y, Ishikawa T, Morii H, Nishizawa Y: Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism. J Clin Endocrinol Metab 2000, 85: 4157\u20134161. 10.1210\/jc.85.11.4157","journal-title":"J Clin Endocrinol Metab"},{"key":"72_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1046\/j.1365-2265.1997.2401045.x","volume":"47","author":"S Nagasaka","year":"1997","unstructured":"Nagasaka S, Sugimoto H, Nakamura T, Kusaka I, Fujisawa G, Sakuma N, Tsuboi Y, Fukuda S, Honda K, Okada K, Ishikawa S, Saito T: Antithyroid therapy improves bony manifestations and bone metabolic markers in patients with Graves' thyrotoxicosis. Clin Endocrinol (Oxf) 1997, 47: 215\u2013221. 10.1046\/j.1365-2265.1997.2401045.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"72_CR12","first-page":"380","volume":"60","author":"GR Williams","year":"2009","unstructured":"Williams GR: Actions of thyroid hormones in bone. Endokrynol Pol 2009, 60: 380\u2013388.","journal-title":"Endokrynol Pol"},{"key":"72_CR13","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.bone.2009.10.031","volume":"46","author":"G Mazziotti","year":"2010","unstructured":"Mazziotti G, Porcelli T, Patelli I, Vescovi PP, Giustina A: Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density. Bone 2010, 46: 747\u2013751. 10.1016\/j.bone.2009.10.031","journal-title":"Bone"},{"key":"72_CR14","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1089\/thy.2010.0457","volume":"21","author":"R Ma","year":"2011","unstructured":"Ma R, Morshed S, Latif R, Zaidi M, Davies TF: The influence of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on osteoclastogenesis. Thyroid 2011, 21: 897\u2013906. 10.1089\/thy.2010.0457","journal-title":"Thyroid"},{"key":"72_CR15","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ejim.2011.03.008","volume":"22","author":"WM Wiersinga","year":"2011","unstructured":"Wiersinga WM: Should we treat mild subclinical\/mild hyperthyroidism? Yes. Eur J Intern Med 2011, 22: 324\u2013329. 10.1016\/j.ejim.2011.03.008","journal-title":"Eur J Intern Med"},{"key":"72_CR16","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.bone.2004.04.021","volume":"35","author":"G Amato","year":"2004","unstructured":"Amato G, Mazziotti G, Sorvillo F, Piscopo M, Lalli E, Biondi B, Iorio S, Molinari A, Giustina A, Carella C: High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. Bone 2004, 35: 785\u2013791. 10.1016\/j.bone.2004.04.021","journal-title":"Bone"},{"key":"72_CR17","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1210\/jcem-38-6-999","volume":"38","author":"R Bouillon","year":"1974","unstructured":"Bouillon R, DeMoor P: Parathyroid function in patients with hyper- or hypothyroidism. J Clin Endocrinol Metab 1974, 38: 999\u20131004. 10.1210\/jcem-38-6-999","journal-title":"J Clin Endocrinol Metab"},{"key":"72_CR18","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1007\/s00198-011-1806-8","volume":"23","author":"MS Ardawi","year":"2012","unstructured":"Ardawi MS, Al-Sibiany AM, Bakhsh TM, Rouzi AA, Qari MH: Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study. Osteoporos Int 2012, 23: 1789\u20131797. 10.1007\/s00198-011-1806-8","journal-title":"Osteoporos Int"},{"key":"72_CR19","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1210\/jc.2011-0566","volume":"96","author":"AG Costa","year":"2011","unstructured":"Costa AG, Cremers S, Rubin MR, McMahon DJ, Sliney J Jr, Lazaretti-Castro M, Silverberg SJ, Bilezikian JP: Circulating sclerostin in disorders of parathyroid gland function. J Clin Endocrinol Metab 2011, 96: 3804\u20133810. 10.1210\/jc.2011-0566","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Thyroid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-6614-5-14.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T21:20:05Z","timestamp":1630531205000},"score":1,"resource":{"primary":{"URL":"https:\/\/thyroidresearchjournal.biomedcentral.com\/articles\/10.1186\/1756-6614-5-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,13]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["72"],"URL":"https:\/\/doi.org\/10.1186\/1756-6614-5-14","relation":{},"ISSN":["1756-6614"],"issn-type":[{"value":"1756-6614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,13]]},"assertion":[{"value":"26 September 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"14"}}